Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care

Area of Science:

• Pharmacology and Cardiovascular Medicine
• Clinical Trial Design and Evidence-Based Medicine

Background:

• Limited long-term data exists for cardiovascular drugs, despite patients often receiving continuous treatment for many years.
• Current randomized clinical trials (RCTs) rarely extend follow-up beyond a few years, creating an evidence gap for long-term efficacy and safety.

Purpose of the Study:

• To examine the benefits and risks associated with the long-term use of commonly prescribed cardiovascular medications.
• To address the limitations of existing clinical trial evidence and the challenges posed by polypharmacy, particularly in elderly patients.

Main Methods:

• Review of evidence from randomized clinical trials (RCTs) for commonly used cardiovascular drug classes (aspirin, statins, beta-blockers, ACE inhibitors) post-myocardial infarction.
• Analysis of pre-licensing trial practices, polypharmacy issues, lack of drug withdrawal evidence, and the roles of regulatory bodies.
• Exploration of potential educational strategies for healthcare professionals regarding long-term medication management.

Main Results:

• Significant evidence gaps exist regarding the long-term benefits and risks of cardiovascular drugs, including aspirin, statins, beta-blockers, and ACE inhibitors.
• Polypharmacy, especially in the elderly, exacerbates the challenges of managing long-term medication use without adequate long-term trial data.
• There is a notable lack of evidence supporting the withdrawal of long-term cardiovascular medications.

Conclusions:

• The current evidence base is insufficient to guide the long-term use of many cardiovascular drugs, necessitating a re-evaluation of trial designs and post-marketing surveillance.
• Recommendations are proposed to improve the understanding and management of long-term drug therapy across cardiovascular diseases and general medicine.
• Addressing polypharmacy and enhancing medical education are crucial for optimizing long-term medication strategies.